A Phase Ib Study of The Safety And Pharmacology of Atezolizumab (Anti−Pd-L1 Antibody) Administered With Ipilimumab, Interferon-Alpha, or Other Immune-Modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 11 Oct 2019
Price : $35 *
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab; Interferon alpha-2b; Ipilimumab; Obinutuzumab; Peginterferon alfa-2a
- Indications Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Roche
- 07 Oct 2019 Planned End Date changed from 16 Aug 2019 to 18 Nov 2019.
- 07 Oct 2019 Planned primary completion date changed from 16 Aug 2019 to 18 Nov 2019.
- 25 Apr 2019 Planned End Date changed from 28 Feb 2019 to 16 Aug 2019.